Dr. Reddy's reported fiscal second-quarter results, which included 2% revenue decline, slightly better than FactSet consensus, and a 24% decline in EBITDA. Shares are flat on the release.
Dr. Reddy's touts a strong track record of new launches across markets, and we expect this to continue over the medium term.
Base business erosion will continue to persist in developed markets and act as a headwind that Dr. Reddy’s must try to offset with new product launches.
|
Metric
|
RDY
|
VTRS
|
TEVA
|
|---|---|---|---|
Price/Earnings (Normalized) | 38.65 | 7.43 | 16.88 |
Price/Book Value | 2.86 | 1.52 | 6.07 |
Price/Sales | 3.22 | 1.48 | 2.71 |
Price/Cash Flow | 21.76 | 7.63 | 15.62 |
|
Metric
|
RDY
|
VTRS
|
TEVA
|
|---|---|---|---|
Quick Ratio | 1.32 | 0.82 | 0.46 |
Current Ratio | 1.93 | 1.58 | 0.88 |
Interest Coverage | 8.21 | −0.38 | 1.79 |
|
Metric
|
RDY
|
VTRS
|
TEVA
|
|---|---|---|---|
Return on Assets (Normalized) | 6.30% | 7.94% | 6.68% |
Return on Equity (Normalized) | 9.56% | 19.79% | 35.32% |
Return on Invested Capital (Normalized) | 8.27% | 11.04% | 14.43% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|@Sv%!w! | LOCK|$yFyP | $70B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|%^&dsh$& | LOCK|N%b>K | $46B | |||
| Haleon PLC ADR
HLN
| LOCK|&n&^%q | LOCK|pgR | $44B | |||
| Zoetis Inc Class A
ZTS
| LOCK|l^?K#Q!@ | LOCK|JR | $32B | |||
| Viatris Inc
VTRS
| LOCK|<m?>lm | LOCK|@gb | $22B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|y#b | LOCK|v%> | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|d@^^@%Z | LOCK|c% | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|Z$@TW@ | LOCK|^?Ky | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|v$$@>< | LOCK|x^s | $2B |
United States